About Pulmonary surfactant-associated protein D
Pulmonary surfactant-associated protein D (SFTPD) is a protein
from Homo sapiens identified by UniProt accession
P35247, 375 residues long.
MolForge cross-references it against 0 known binders and
375 disease associations.
Target properties
| Protein name | Pulmonary surfactant-associated protein D |
| UniProt accession | P35247 |
| Gene | SFTPD |
| Organism | Homo sapiens |
| Length | 375 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (375)
Diseases linked to this target (Open Targets).
- chronic obstructive pulmonary disease · score 0.46
- COVID-19 · score 0.39
- severe acute respiratory syndrome · score 0.38
- blood protein measurement · score 0.36
- FEV/FVC ratio · score 0.31
- surfactant protein D measurement · score 0.25
- rheumatoid arthritis · score 0.25
- cutaneous melanoma · score 0.24
- hemoglobin measurement · score 0.16
- mean corpuscular hemoglobin concentration · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35247-F1 | alphafold | PREDICTED | 65.51 | — |
Amino-acid sequence (375 residues)
MLLFLLSALV LLTQPLGYLE AEMKTYSHRT MPSACTLVMC SSVESGLPGR DGRDGREGPR GEKGDPGLPG AAGQAGMPGQ AGPVGPKGDN GSVGEPGPKG DTGPSGPPGP PGVPGPAGRE GPLGKQGNIG PQGKPGPKGE AGPKGEVGAP GMQGSAGARG LAGPKGERGV PGERGVPGNT GAAGSAGAMG PQGSPGARGP PGLKGDKGIP GDKGAKGESG LPDVASLRQQ VEALQGQVQH LQAAFSQYKK VELFPNGQSV GEKIFKTAGF VKPFTEAQLL CTQAGGQLAS PRSAAENAAL QQLVVAKNEA AFLSMTDSKT EGKFTYPTGE SLVYSNWAPG EPNDDGGSED CVEIFTNGKW NDRACGEKRL VVCEF
Explore Pulmonary surfactant-associated protein D with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets